LuciTepo (Tepotinib) 225mg*60 | Laos Generic MET Inhibitor | GLT

Generic Information: LuciTepo (Tepotinib) 225mg — Laos

LuciTepo is a Lao-manufactured generic of tepotinib, the oral MET tyrosine kinase inhibitor developed by Merck KGaA (Darmstadt, Germany) and approved worldwide under the brand name Tepmetko. This listing is the standard presentation: 225 mg film-coated tablets in a 60-tablet bottle. LuciTepo is produced by Lucius Pharmaceuticals (Lao) Co., Ltd., a Vientiane-based manufacturer that focuses on oncology generics and has built a portfolio of targeted-therapy products for Southeast Asian and international patients.

Because tepotinib is taken at 450 mg once daily — two 225 mg tablets a day — one 60-tablet bottle of LuciTepo covers a full 30-day month of treatment. Buyers should confirm the "tepotinib 225 mg" marking on the pack, as the active ingredient is the critical identity marker across all generics.

What Is LuciTepo Used For?

LuciTepo is prescribed for metastatic non-small cell lung cancer (NSCLC) that carries a MET exon 14 skipping mutation. This is a rare but clinically important driver mutation found in a small subset of NSCLC patients, and tepotinib is one of the targeted therapies designed specifically for it. LuciTepo is used in adults whose disease has progressed or who are not candidates for other treatment options, following confirmation of the mutation by an approved diagnostic test.

How Does LuciTepo Work?

Tepotinib selectively inhibits the MET (mesenchymal-epithelial transition) receptor tyrosine kinase. In tumours with MET exon 14 skipping, this kinase is left switched on because the normal degradation signal is missing, driving uncontrolled cell growth. By blocking MET signalling, LuciTepo slows or stops the growth of these cancer cells. Its selectivity for MET is what makes it a targeted, rather than broadly cytotoxic, therapy.

Indications

• Metastatic non-small cell lung cancer with MET exon 14 skipping mutation, confirmed by a validated test.
• Used in adult patients, including those previously treated and those for whom other options are unsuitable.

Dosage and Administration

The recommended dose is 450 mg once daily, taken as two 225 mg tablets at the same time, with or without food. Tablets should be swallowed whole with water and not crushed or split. A 60-tablet bottle therefore provides 30 days of therapy. The prescribing physician may adjust or interrupt dosing based on tolerability, liver function and other laboratory results, and treatment continues as long as benefit is maintained.

Side Effects

The most common side effects of tepotinib include peripheral oedema (swelling, especially of the legs), nausea, diarrhoea, fatigue and decreased appetite. Liver enzyme elevations are notable and require periodic blood monitoring; more serious but less common effects include interstitial lung disease/pneumonitis and QT interval changes. Patients should report new or worsening breathlessness, cough or swelling promptly.

Storage

Store LuciTepo below 30°C in the original bottle, protected from moisture and direct light, and out of the reach of children. Do not use after the expiry date printed on the label.

Why Choose the GLT?

GLT sources LuciTepo through a documented Lao supply chain and confirms each batch against the manufacturer's details before shipping, which matters for buyers who need a dependable, traceable generic alternative. Lao and other regional generics of tepotinib are typically priced at a fraction of the branded originator sold in Western markets — often several times lower — which makes long-term MET-targeted therapy far more sustainable for patients and institutions. We provide clear purchase documentation and direct contact for ongoing support.

How to Order LuciTepo from GLT

To order LuciTepo (tepotinib 225 mg, 60 tablets), contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the quantity you need, your shipping destination, and whether you require a prescription or purchase order. We confirm batch details and lead time before dispatch and support both individual and institutional orders.

FAQ

Is LuciTepo the same as Tepmetko? LuciTepo contains the same active ingredient (tepotinib) at the same 225 mg dose as Tepmetko; it is a generic manufactured in Laos by Lucius Pharmaceuticals rather than by Merck KGaA.

What is MET exon 14 skipping? It is a mutation in the MET gene that removes a regulatory exon, leaving the MET receptor persistently active and driving NSCLC growth; tepotinib specifically targets this abnormality.

How long does one bottle of LuciTepo last? At the standard 450 mg daily dose (two 225 mg tablets), one 60-tablet bottle lasts 30 days.